Frontage Laboratories, Inc., part of Frontage Holdings Corporation, has expanded its capabilities with the launch of a new Contract Research, Development, and Manufacturing Organization (CRDMO) facility in Exton, Pennsylvania. This state-of-the-art, 46,300-square-foot Good Manufacturing Practice $(GMP.UK)$ facility enhances Frontage's service offerings in drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support. The facility features nine GMP suites tailored to diverse manufacturing needs, including high-potent, aseptic, and non-sterile suites, and is equipped to handle a variety of pharmaceutical forms such as injectables, tablets, and nasal preparations. The expansion underscores Frontage's commitment to accelerating pharmaceutical and biotech innovation by providing a comprehensive, one-stop-shop solution for clinical supplies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.